GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
2.4k
c/trialwatch·posted 9 months ago by u/emil_agyeman

small win: hazard ratio stopped being a problem at week 51

Paper Sourced ×2 Long Haul ×1

Quick one. Canada here.

SURPASS works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.

Specifics: the route I used took 4 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.

Happy to answer questions from anyone in the same jurisdiction.

2,678 up / 306 down90% upvoted52 commentsid 12x76r11 Oct 2025

52 comments

20 in this archive, depth 4

best — the order this archive was captured in

u/zaid_roos233 points·9 months ago·edited

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/hazard_ratio_halMOD140 points·9 months ago·edited

Removed a chain here. The rule is one line long and it is not negotiable.

replysharereportpermalink
u/ferran_dahlberg189 points·9 months ago·edited

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/nils_tulloch244 points·9 months ago
the VendorInvestigate number or it did not happen
replysharereportpermalink
u/renal_outcomes_rnephro-curious94 points·9 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/emil_agyemanOP52 points·9 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/enzo_ferrari29 points·9 months ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
load more comments (1) →
u/oskar_ibarra108 points·9 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
[removed]71 points·9 months ago

[removed by moderator]

replysharereportpermalink
u/ahmed_iyer102 points·9 months ago

Slight fix: the number was 98.0, not 98.1. Decimal point, but a fairly consequential one.

replysharereportpermalink
u/rania_salinas50 points·9 months ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/forest_plot_fionastats121 points·9 months ago

Phase 2 or phase 3?

replysharereportpermalink
u/nora_oyelaran95 points·9 months ago

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

replysharereportpermalink
u/first_hundred76 points·9 months ago·edited

the 3 week readout is different from the 21 week readout

replysharereportpermalink
u/curious_panel_only48 points·9 months ago

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

replysharereportpermalink
u/nora_oyelaran56 points·9 months ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/oskar_ibarra14 points·9 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/valeria_karlsen27 points·9 months ago

the discontinuation arms are the interesting part, not the FLOW endpoints

replysharereportpermalink
u/milos_vanhecke10 points·9 months ago

off-label use data is different from approved-indication data

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.